SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03294460

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Nicotinic Receptor Genetic Variation and Alcohol Reward

Background: People with the brain disease AUD (alcohol use disorder) have a serious problem with drinking. Researchers want to study how different people react to alcohol, and how genes affect this. They will focus on a nicotine receptor gene that may increase a person s AUD risk. Objectives: To see if people with variations of a nicotine receptor gene take alcohol differently and have different brain responses to alcohol cues. Eligibility: Healthy adults ages 21 - 60. This study includes smokers and non-smokers. Design: Participants will be screened under another protocol. Participants will have three 9-hour visits. They must have no alcohol or non-prescription drugs before all visits and no food or drink before 2 visits. At every visit, participants will: - Get a light meal - Have breath and urine tests - Get taxi rides there and back At visits 1 and 3, participants will: - Have a thin plastic tube inserted in an arm and connected to a pump for alcohol infusion. - Have sensors on their chest to monitor heart rate. - Sit in a chair for 2.5 hours and get alcohol by pushing a button. Their breath alcohol level will be monitored. - Answer questions about mood and effects of alcohol - Give blood samples - Relax at the clinic while their breath alcohol level drops At visit 2, participants will: - Answer questions and do computer tests - Have an alcoholic drink and a snack - Have a magnetic resonance imaging (MRI) scan. They will lie in a machine that takes pictures of the brain. They will do computer tasks. - Have another drink and snack - Relax until their alcohol level drops Participants will have a follow-up call after each visit.

NCT03294460 Alcohol Drinking
MeSH: Alcohol Drinking

3 Interventions

Name: Alcohol (Oral)

Description: Oral Self-administration

Type: Drug

1

Name: Alcohol (IV)

Description: IV Self-administration

Type: Drug

1

Name: Alcohol (Ethanol)

Description: IV and Oral Self-administration

Type: Drug

1


Primary Outcomes

Measure: To examine the effect of CHRNA5 (rs16969968) genetic variation on neural correlates of incentive salience for alcohol, as measured by BOLD response during the Alcohol-Food Incentive Delay (AFID) task using fMRI.

Time: Study Completion

Measure: To examine the effect of CHRNA5 (rs16969968) genetic variation on IV alcohol self-administration, as measured by BrAC exposure (peak BrAC, number of infusions, time to binge-level) in non-smoking, non-dependent drinkers.

Time: Study Completion

Secondary Outcomes

Description: associated with the salience network, including dorsal anterior cingulate cortex, ventral striatum and extended amygdala in non-smoking non-dependent drinkers.

Measure: To examine the effect of CHRNA5 (rs16969968) genetic variation on resting-state functional connectivity (rsFC) among brain regions

Time: Study Completion

Measure: To examine the effect of CHRNA5 (rs16969968) genetic variation on the rate of IV alcohol self-administration, as measured by the preferred rate during the second IV-ASA session in non-smoking, non-dependent drinkers.

Time: Study Completion

Measure: To examine the relationship between fMRI measures (BOLD response during AFID and rsFC measures) and IV alcohol self-administration, and any differences in the degree of association among these measures by CHRNA5 genotype.

Time: Study Completion

Purpose: Basic Science

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 rs16969968

To examine the effect of CHRNA5 (rs16969968) genetic variation on neural correlates of incentive salience for alcohol, as measured by BOLD response during the Alcohol-Food Incentive Delay (AFID) task using fMRI.. null.

To examine the effect of CHRNA5 (rs16969968) genetic variation on IV alcohol self-administration, as measured by BrAC exposure (peak BrAC, number of infusions, time to binge-level) in non-smoking, non-dependent drinkers.. null.

To examine the effect of CHRNA5 (rs16969968) genetic variation on resting-state functional connectivity (rsFC) among brain regions.

associated with the salience network, including dorsal anterior cingulate cortex, ventral striatum and extended amygdala in non-smoking non-dependent drinkers.. To examine the effect of CHRNA5 (rs16969968) genetic variation on the rate of IV alcohol self-administration, as measured by the preferred rate during the second IV-ASA session in non-smoking, non-dependent drinkers.. null.

There has been a great interest in examining variation in target genes that may play a mechanistic role in the expression of these endophenotypes, such the missense single-nucleotide polymorphism (SNP) in the gene encoding the 5 subunit of the nicotinic acetylcholine receptor (CHRNA5) - rs16969968.

Participants will be stratified into equally-sized groups based on their smoking status (smokers and non-smokers) and rs16969968 genotype: 1).



HPO Nodes